House of Commons
EDM #1531
Tabled 17 July 2018
2017-19 Session
That this House welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend dinutuximab beta for the treatment of children with high-risk neuroblastoma; praises the collaborative and flexible approach of all parties including NICE, EUSA Pharma, Solving Kids' Cancer, Neuroblastoma UK, the Children's Cancer and Leukaemia group, JACK, the Bradley Lowery Foundation, Hugs from Henry, Christopher's Smile, Niamh's Next Steps and Smile with Siddy, Grace Kelly Ladybird Trust, Rupert's Revenge Trust, Stacey's Smiles, Harvey Hext Trust, George and the Giant Pledge and Abbie's Army; notes the dedication and involvement of the clinical community in supporting the appraisal process; and calls on the House to praise the bravery of all those children suffering from high-risk neuroblastoma in the UK today.

Signatures (35)

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.
In addition to the sponsors, the following Members have signed to support the motion.
There are no withdrawn signatures for this Motion